Heron Therapeutics (HRTX) PT Raised to $46 at Leerink Partners; 'Focus Moving to HTX-011's Commercialization'

Heron Therapeutics (HRTX) Prices $200M Common Share Offering

Heron Therapeutics, Inc. (NASDAQ: HRTX) today announced the pricing of an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of... More

Heron Therapeutics (HRTX) PT Raised to $80 at Evercore ISI

Evercore ISI raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $80.00 (from $56.00) while maintaining a Outperform rating.

Heron Therapeutics (HRTX) PT Raised to $44 at BofA/Merrill Lynch

BofA/Merrill Lynch raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $44.00 (from $33.00) while maintaining a Buy rating.

Heron Therapeutics (HRTX) PT Raised to $50 at Oppenheimer

Oppenheimer raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $50.00 (from $34.00) while maintaining a Outperform rating.

Heron Therapeutics (HRTX) PT Raised to $41 at Mizuho Securities

Mizuho Securities raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $41.00 (from $35.00) while maintaining a Buy rating.

Heron Therapeutics (HRTX) PT Raised to $66 at Needham & Company

Needham & Company raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $66.00 (from $42.00) while maintaining a Buy rating.

Analyst Serge Belanger commented, "HRTX reported positive results from two Phase 2b studies in total knee arthroplasty (TKA) and breast augmentation where HTX-011 successfully... More

Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ Opportunity

Cowen raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $54.00 (from $48.00) while maintaining an Outperform rating after the company announced positive Phase IIb data in TKA and breast augmentation demonstrating superior pain control and opioid reduction compared to placebo and generic bupivacaine. In addition HTX-011... More

Heron Therapeutics (HRTX) PT Raised to $51 at Jefferies

Jefferies raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $51.00 (from $38.00) while maintaining a Buy rating.

Heron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISI

Evercore ISI raised its price target on Heron Therapeutics (NASDAQ: HRTX) to a 'Street High' $80.00 (from $56.00) while maintaining an Outperform rating.

Analyst Josh Schimmer with the rating news.